Osteoporosis is the progressive, systemic skeletal disease characterized by decreased bone mass and micro-architectural deterioration of bone tissue leading to increased bone fragility and susceptibility to fractures.
The more risk factors (eg history, of fracture, advanced age, comorbidities, impaired vision) that are present, the greater the risk of fracture.
Administration of the RANKL* inhibitor denosumab prior to chemotherapy initiation may prevent secondary reduction in bone mineral density (BMD) induced by chemotherapy, according to the ESPRESSO-02 study presented at ESMO Asia 2018.
Zoledronate significantly reduces the risk of both nonvertebral and vertebral fragility fractures over 6 years in older women with osteopenia — a substantial patient group at risk for fractures but in whom a knowledge gap remains for pharmacological treatment, reveals a large randomized trial.
Older individuals with osteoporosis who adopt a Mediterranean diet and take vitamin D supplements may experience significant improvements in femoral neck bone mineral density (BMD), according to the European-based NU-AGE* trial.
Treatment with denosumab in postmenopausal women with osteoporosis for 2 and/or 3, 5, and 10 years, compared with placebo, correlates with normal histology, low bone remodelling rate, increased matrix mineralization and lower mineralization heterogeneity, a recent study has shown. Such variables persist from years 5–10.
The RANKL* inhibitor denosumab is superior to the bisphosphonate risedronate in improving lumbar spine bone mineral density (BMD) at 1 year in patients newly starting or continuing steroid therapy, thus presenting a new treatment option for steroid-induced osteoporosis, a global study has shown.
Long-term use of inhaled corticosteroids (ICSs) at daily doses of ≥1,000 µg was associated with a modest but significant increase in nonvertebral fracture risk in patients with chronic obstructive pulmonary disease (COPD), according to a real-world study.
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.